- Home
- OSUR vs ACIU Comparison
OSUR vs ACIU Comparison
Compare OSUR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- ACIU
- Stock Information
- Founded
- OSUR 2000
- ACIU 2003
- Country
- OSUR United States
- ACIU Switzerland
- Employees
- OSUR N/A
- ACIU N/A
- Industry
- OSUR Medical/Dental Instruments
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- ACIU Health Care
- Exchange
- OSUR Nasdaq
- ACIU Nasdaq
- Market Cap
- OSUR 289.4M
- ACIU 332.4M
- IPO Year
- OSUR 1986
- ACIU 2016
- Fundamental
- Price
- OSUR $3.87
- ACIU $3.20
- Analyst Decision
- OSUR Buy
- ACIU Strong Buy
- Analyst Count
- OSUR 3
- ACIU 2
- Target Price
- OSUR $6.67
- ACIU $12.00
- AVG Volume (30 Days)
- OSUR 771.3K
- ACIU 144.4K
- Earning Date
- OSUR 11-06-2024
- ACIU 11-05-2024
- Dividend Yield
- OSUR N/A
- ACIU N/A
- EPS Growth
- OSUR N/A
- ACIU N/A
- EPS
- OSUR 0.15
- ACIU N/A
- Revenue
- OSUR $224,263,000.00
- ACIU $48,505,404.00
- Revenue This Year
- OSUR N/A
- ACIU $85.33
- Revenue Next Year
- OSUR N/A
- ACIU $80.69
- P/E Ratio
- OSUR $25.02
- ACIU N/A
- Revenue Growth
- OSUR N/A
- ACIU 4097200.00
- 52 Week Low
- OSUR $3.72
- ACIU $2.25
- 52 Week High
- OSUR $8.45
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- OSUR 44.24
- ACIU 47.84
- Support Level
- OSUR $3.80
- ACIU $3.16
- Resistance Level
- OSUR $4.01
- ACIU $3.48
- Average True Range (ATR)
- OSUR 0.14
- ACIU 0.20
- MACD
- OSUR -0.00
- ACIU -0.01
- Stochastic Oscillator
- OSUR 41.67
- ACIU 12.82
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.